Morphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration.

Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi

Abstract read

In one paragraph

Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taiichi HikichiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan. thikichi@hikichi-eye.jp.

Haruka KurabeHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.

Amane NotoyaHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.

Yuuna OguroHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.

Misaki HiranoHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.

Yumeka DoiHikichi Eye Clinic, Kita-7 Nishi-5 7-1 Kita-Sky-BuildingKita-ku, Sapporo, 060-0807, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate longitudinal morphologic changes of the double-layer sign (DLS) on optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (nAMD) presenting with exudative macular neovascularization (eMNV) undergoing anti-vascular endothelial growth factor (VEGF) therapy.

methodsThis retrospective study included 207 consecutive treatment-naïve eyes (207 patients) with nAMD presenting with eMNV and a DLS treated with intravitreal anti-VEGF injections and were followed for ≥ 12 months. All eyes received 3 monthly loading injections followed by either treat-and-extend (TAE) or pro re nata (PRN) retreatment, per predefined criteria. DLS area, length, and height were measured at baseline, after loading, and 12 months.

resultsAll 207 eyes demonstrated significant reductions in mean (± standard deviation) DLS area, length, and height 1 month after the third monthly injection (165 ± 188 µm

conclusionDLS morphology regresses after anti-VEGF therapy, and persistent or recurrent fluid is associated with less durable regression. The DLS regresses in response to anti-VEGF therapy, and its behaviour correlates with the clinical course of exudative MNV associated with a DLS. DLS monitoring may complement-but not replace-multimodal imaging when assessing MNV activity.

Indexed as

Angiogenesis InhibitorsBevacizumabMacula LuteaRanibizumabTomography, Optical CoherenceVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AAnti-vascular endothelial growth factor therapyDouble-layer signExudative age-related macular degenerationOptical coherence tomography

Identifiers

PMID40875052

DOI10.3390/biom14030252

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.